High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$488K
$488,591
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
|
CTNM
S
Contineum Therapeutics, Inc.
Lorrain Daniel S.
• Officer • Chief Scientific Officer
10b5-1 Sell
2026-03-02
$62,585
|
||||||
| CTNM |
Contineum Therapeutics, Inc.
|
Officer • Chief Scientific Officer
10b5-1 Sell
|
2026-03-02 | $62,585 | S | Form 4 |
|
CTNM
S
Contineum Therapeutics, Inc.
Watkins Tim
• Officer • CMO & Head of Development
10b5-1 Sell
2026-03-02
$54,220
|
||||||
| CTNM |
Contineum Therapeutics, Inc.
|
Officer • CMO & Head of Development
10b5-1 Sell
|
2026-03-02 | $54,220 | S | Form 4 |
|
CTNM
S
Contineum Therapeutics, Inc.
Lorrain Daniel S.
• Officer • Chief Scientific Officer
10b5-1 Sell
2026-02-25
$61,228
|
||||||
| CTNM |
Contineum Therapeutics, Inc.
|
Officer • Chief Scientific Officer
10b5-1 Sell
|
2026-02-25 | $61,228 | S | Form 4 |
|
CTNM
S
Contineum Therapeutics, Inc.
Stengone Carmine N.
• CEO
10b5-1 SellΔOwn -15.3%
2026-02-25
$43,242
|
||||||
| CTNM |
Contineum Therapeutics, Inc.
|
CEO
10b5-1 SellΔOwn -15.3%
|
2026-02-25 | $43,242 | S | Form 4 |
|
CTNM
S
Contineum Therapeutics, Inc.
Lorrain Daniel S.
• Officer • Chief Scientific Officer
10b5-1 Sell
2026-02-24
$68,936
|
||||||
| CTNM |
Contineum Therapeutics, Inc.
|
Officer • Chief Scientific Officer
10b5-1 Sell
|
2026-02-24 | $68,936 | S | Form 4 |
|
CTNM
S
Contineum Therapeutics, Inc.
Stengone Carmine N.
• CEO
10b5-1 SellΔOwn -22.7%
2026-02-24
$70,486
|
||||||
| CTNM |
Contineum Therapeutics, Inc.
|
CEO
10b5-1 SellΔOwn -22.7%
|
2026-02-24 | $70,486 | S | Form 4 |
|
CTNM
S
Contineum Therapeutics, Inc.
Lorrain Daniel S.
• Officer • Chief Scientific Officer
10b5-1 Sell
2026-02-19
$1,600
|
||||||
| CTNM |
Contineum Therapeutics, Inc.
|
Officer • Chief Scientific Officer
10b5-1 Sell
|
2026-02-19 | $1,600 | S | Form 4 |
|
CTNM
S
Contineum Therapeutics, Inc.
Lorrain Daniel S.
• Officer • Chief Scientific Officer
10b5-1 Sell
2026-02-11
$6,400
|
||||||
| CTNM |
Contineum Therapeutics, Inc.
|
Officer • Chief Scientific Officer
10b5-1 Sell
|
2026-02-11 | $6,400 | S | Form 4 |
| CTNM |
Contineum Therapeutics, Inc.
|
CEO
10b5-1 Sell
|
2026-02-11 | $6,400 | S | Form 4 |
|
CTNM
S
Contineum Therapeutics, Inc.
Lorrain Daniel S.
• Officer • Chief Scientific Officer
10b5-1 Sell
2026-02-03
$62,305x2
|
||||||
| CTNM |
Contineum Therapeutics, Inc.
|
Officer • Chief Scientific Officer
10b5-1 Sell
|
2026-02-03 | $62,305x2 | S | Form 4 |
|
CTNM
S
Contineum Therapeutics, Inc.
Watkins Tim
• Officer • CMO & Head of Development
10b5-1 SellΔOwn -77.5%
2026-01-28
$51,188x2
|
||||||
| CTNM |
Contineum Therapeutics, Inc.
|
Officer • CMO & Head of Development
10b5-1 SellΔOwn -77.5%
|
2026-01-28 | $51,188x2 | S | Form 4 |